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Treatment with Anakinra Improves Disposition Index
But Not Insulin Sensitivity in Nondiabetic Subjects
with the Metabolic Syndrome: A Randomized,
Double-Blind, Placebo-Controlled Study
Edwin J. P. van Asseldonk, Rinke Stienstra, Tim B. Koenen, Leo A. B. Joosten,
Mihai G. Netea, and Cees J. Tack
Department of Internal Medicine, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The
Netherlands
Context: Obesity induces low-grade inflammation that may promote the development of insulin
resistance. IL-1 is one of the key inflammatory factors.
Objective: The objective of the study was to demonstrate improvement of insulin sensitivity by
blocking IL-1.
Design: This was a randomized, double-blind, crossover study.
Setting: The study was based on ambulatory care.
Participants: Participants included nondiabetic, obese subjects with the metabolic syndrome.
Intervention: Intervention included 150 mg anakinra sc once daily or matching placebo for 4 wk.
Main Outcome Measure: Insulin sensitivity as measured by euglycemic hyperinsulinemic clamp.
Results:A total of 13 of 19 subjects completed the study. Although anakinra treatment resulted
in a significantly lower level of inflammation illustrated by a reduction in circulating C-reactive
protein concentrations and leukocyte numbers, insulin sensitivity was not significantly differ-
ent after anakinra treatment (2.8 102 0.5 102) comparedwith placebo treatment (2.4
102  0.3  102 mol/kg1  min1  pmol1, P  0.15). Adipose tissue examination, per-
formed to analyze local effects of IL-1 receptor antagonist, showed an increased influx of
macrophages after treatmentwith anakinramost likely due to an injection site reaction caused
by the vehicle (0.28  0.05 vs. 0.11  0.01 macrophages per adipocyte, P  0.005). The differ-
ences in individual subject insulin sensitivity after anakinra as comparedwith placebo between
subjects were negatively correlated with macrophage infiltration into the adipose tissue (r2
0.46, P  0.01). The disposition index increased significantly after anakinra treatment (P 
0.04), reflecting an improvement in -cell function.
Conclusions:Our results suggest thatanakinradoesnot improve insulin sensitivity inobese, insulin-
resistant, nondiabetic subjects. (J Clin Endocrinol Metab 96: 2119–2126, 2011)
The global prevalence of obesity is rapidly rising andparalleled by an increasing incidence of insulin re-
sistance and type 2 diabetes mellitus. Although the
pathophysiological basis underlying obesity-associated
insulin resistance has not been fully unraveled, many
reports suggest that chronic low-grade inflammation
originating from adipose tissue represents an important
link (1).
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Storage of excess energy results in expansion of adipose
tissue mass and an increase in adipocyte size. Concurrent
with this expansion, oxygen delivery to the adipocyte is
decreased and may eventually lead to microhypoxia and
adipocyte death. Together with the enhanced proinflam-
matoryprofileof enlargedadipocytes (2), this results in the
recruitment of macrophages that further amplify the in-
flammatory status of the adipose tissue (3). Proinflam-
matory cytokines such as TNF and IL-6 that are re-
leased in increased amounts by adipocytes and activated
macrophages of obese individuals can induce insulin
resistance (4, 5).
The proinflammatory cytokine IL-1 is also involved in
the development of diabetes mellitus. By inducing -cell
destruction, IL-1 contributes to the pathogenesis of type 1
diabetes mellitus (6). Furthermore, a positive association
between IL-1 levels and the presence of obesity has been
found (7). IL-1 induces insulin resistance in cultured hu-
man adipocytes (8) and primary rat hepatocytes (9), and
IL-1 knockout mice are more insulin sensitive as their
wild-type littermates (10, 11). Based on these observa-
tions, one might expect that blockade of IL-1would im-
prove insulin resistance in humans.
IL-1 exerts its effects by binding to the type 1 IL-1 re-
ceptor (IL-1R) (12). This results in recruitment of IL-1
receptor accessory protein, necessary for signal transduc-
tion (13). Activation of IL-1R leads to fever, synthesis of
acute phase proteins, leukocytosis, thrombocytosis, and
anemia (14). IL-1 receptor antagonist (IL-1Ra) inhibits
IL-1 action by competing with IL-1 for binding to the
IL-1R. Binding of IL-1Ra to the IL-1R does not result in
recruitmentof IL-1 receptor accessoryprotein and thereby
blocks intracellular signaling (13).
Blocking the IL-1 effects in patientswith type2diabetes
mellitus by anakinra, a recombinant human IL-1Ra, has
been shown to improve glycemic control (15). Whether
IL-1 blockade has a beneficial effect on insulin sensitivity
in nondiabetic subjects characterized by insulin resistance
remains to be determined.
In the present study, we investigated whether blocking
IL-1 by recombinant IL-1Ra in humans for 4 wk can im-
prove insulin sensitivity in nondiabetic, obese subjects
with the metabolic syndrome.
Subjects and Methods
Study design
Overweight subjects with the metabolic syndrome, yet no
type 2 diabetes mellitus, were included in this randomized, dou-
ble-blind, placebo-controlled, two-period, crossover study. Sub-
jects were recruited by means of advertisements in a local news-
paper and from the outpatient clinic of the Radboud University
Nijmegen Medical Centre. We compared anakinra with match-
ing placebo. Study medication was self-administrated sc once
daily for 4wk.Betweenboth treatment periods, therewas a4-wk
washout. Because prior studies suggest that the conventional
dose of 100 mg anakinra once daily is not sufficient in patients
with high body weight (15), the dose was increased to 150 mg
daily. This dose has been applied in patients with rheumatoid
arthritis (16).
Anakinra was purchased from the regular manufacturer
(Biovitrum, Stockholm, Sweden). The Pharmacy Department of
Radboud University Nijmegen Medical Centre prepared all
study medication and was responsible for the blinding and ran-
domization procedure. Subjects were randomized in blocks of
four in a 1:1 allocation ratio.
Participants
The study was approved by the institutional ethics re-
view board and assessed by an independent monitor. Written
informed consent was obtained from all subjects before
randomization.
Inclusion criteria were age 18 yr or older, body mass index
greater than 30 kg/m2, and three or more characteristics of the
metabolic syndrome according to the definition of the third re-
port of the National Cholesterol Education Program’s Adult
Treatment Panel (17). Exclusion criteria were the known pres-
ence of diabetesmellitus, a fasting plasma glucose 7.0mmol/liter
or higher, glycosylated hemoglobin (HbA1c) 6.2% or higher,
immunodeficiencyor immunosuppressive treatment, current use
of antiinflammatory medication (100 mg aspirin per day was
allowed), signs of current infection or treatmentwith antibiotics,
a history of recurrent infections or tuberculosis, pregnancy or
breast-feeding, a serum alanine aminotransferase or aspartate
aminotransferase level ofmore than3 times the upper limit of the
normal range, a serum creatinine level higher than 130 mol/
liter, neutropenia (a leukocyte count of less than 2  109/liter),
or the presence of any other medical condition that might inter-
fere with the current study protocol and inability to give in-
formed consent.
Study procedures
At the end of both treatment periods, we performed a eu-
glycemic hyperinsulinemic clamp (insulin infusion rate 360
pmol/m2  min (18) and on a separate day a 75-g oral glucose
tolerance test.
A sc fat biopsy was obtained. All study procedures were per-
formed after an overnight fast.
Subcutaneous adipose tissue biopsy
A sc adipose tissue biopsy was taken just before the clamp,
about 30 min after a sc injection with placebo or anakinra to
analyze local effects of the active substance (recombinant IL-
1Ra) of anakinra. Biopsies were taken under local anesthesia
(2%LidocaineHCl) fromanarea thatwas not affected by a local
injection site reaction causedby the vehicle of anakinra, about 10
cm lateral of the umbilicus using a Hepafix Luer lock syringe
(Braun,Melsungen,Germany) anda2.10-80-mmBraunmed-
ical Stericanneedle (Braun).Theadipose tissuewaswashedusing
a 0.9% normal saline solution. The adipose tissue was snap fro-
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zen and stored at 80 C until further analysis or fixated in 4%
paraformaldehyde for embedding in paraffin.
Immunohistochemistry
An antibody against the cluster of differentiation 68 (CD68;
AbD Serotec, Kidlington, UK) was used to stain macrophages.
Immunohistochemistry was performed as described earlier (19).
Macrophage influx was quantified by counting the number of
adipocytes and macrophages in four representative fields of ad-
ipose tissue. A mean number of 609  24 adipocytes were
counted per subject for each treatment period.
RNA isolation and real-time PCR analysis
Total RNA was extracted from sc adipose tissue using TRIzol
reagent (Invitrogen,Carlsbad,CA).RNAconcentrationwas deter-
mined using the NanoDrop (NanoDrop Technologies, Wilming-
ton,MA). cDNA synthesis was performed using the iScript cDNA
synthesis kit (Bio-RadLaboratories,Hercules,CA).Real-timePCR
wasperformedusing Power-SYBRGreenmastermix and the 7300
real-time PCR system (Applied Biosystem, Warrington, UK). Ex-
pression of genes was normalized to 2M gene expression levels.
Used primer sequences were: 2M, ATGAGTATGCCTGCCGT-
GTG (sense), CCAAATGCGGCATCTTCAAAC (antisense); per-
oxisomeproliferator-activated receptor (PPAR), ATTGACCCA-
GAAAGCGATTCC (sense), TCTTCCATTACGGAGAG, ATC-
CAC (antisense); fatty acid binding protein 4 (FABP4), AGCAC-
CATAACCTTAGATGGGG (sense), CGTGGAAGTGACGCCTT-
TCA (antisense); adiponectin, ATCGGTGAAACCGGAGTACC
(sense), GCATGTTGGGGATAGTAACGTAA (antisense).
Biochemical analysis
Glucose concentrations were measured using the oxidation
method (Glucose Analyzer 2; Beckman Instruments Inc., Fuller-
ton, CA). Plasma concentrations of total adiponectin, IL-6, IL-
1Ra, high-sensitivity C-reactive protein (hsCRP), and proinsulin
were determined using ELISA [R&D Systems, Minneapolis,
MN; proinsulin: Millipore, Billerica, MA; hsCRP in-house de-
veloped ELISA by University Hospital Maastricht (20)]. Insulin
levels were determined by a RIA. For C-peptide determination,
chemiluminescence was used. Inter- and intraassay coefficients
of variationwere, respectively: adiponectin, 2.7 and 1.3%; IL-6,
3.3 and 5.0%; IL1-ra, 5.0 and 8.0%; hsCRP, 4.7 and 3.8%;
insulin, 9.7 and 4.7%; and proinsulin 4.7 and 5.6%.
Measurements of other parameters were performed in the
clinical laboratory unit of the Radboud University Nijmegen
Medical Centre.
Statistical analysis
Weconsidered a 20% improvement of the primary end point,
insulin sensitivity, as determined by euglycemic hyperinsuline-
mic clamp, as clinically relevant. Assuming a test-to-test corre-
lationcoefficientof0.5 (paired tests) andameanglucose infusion
rate of 30 7 mol/kg/min would require a total of 11 subjects
todetect a20%change in insulin sensitivitywith apowerof 80%
at a significance level of 0.05. Dropouts were replaced.
Differences were analyzed by the Student’s t test. Correlation
analysis was performed by regression analysis. Two-tailed P 
0.05 was considered to denote significance. Data are presented
as mean  SEM.
Results
Nineteen of the 32 initially screened subjects underwent
randomization and were enrolled in the study between
June and October of 2009. A total of 13 subjects, nine
females and four males, completed the study. Nine of the
13 subjects who completed the study used anakinra in the
second treatment period. Two of the six dropouts used
anakinra in the second treatment period. Two subjects
were discontinued from the study due to an infection, one
had an H1N1 infection (during anakinra treatment) and
one had a wound infection (during placebo treatment in
the first treatment period). Two subjects withdrew due to
the physical load of the tests and two subjects withdrew
due to injection site reactions (Fig. 1). Dropouts were sig-
nificantly younger (P  0.008), had a higher body mass
index (P  0.02), and had a larger waist circumference
(P  0.05) in comparison with study subjects that com-
pleted the study. All other parameters were similar be-
tween study subjects that withdrew or completed the
study.
The trial was terminated after the last subject com-
pleted all studies in February 2010. Baseline characteris-
tics of all subjects that completed the study are shown in
Table 1.
Twelve of 13 subjects experienced local injection site
reactions (Fig. 2B) of varying severity. No other adverse
Assessed for eligibility (n=32) 
Excluded (n=13) 
- Not meeting inclusion criteria (n=12) 
- Refused to participate (n=1) 
Analysed (n=13) 
results of paired data were compared intra-
individually 
Discontinued intervention (n=6) 
- Injection side reaction ( n=2) 
- Physical load of tests (n=2) 
- H1N1 infect (n=1) 
- Wound infect (n=1)
Received intervention (n=19) 
Randomized (n=19)
FIG. 1. Design, enrollment, withdrawal, and completion of the study.
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events were observed during the study. Sufficiency of the
intervention was assessed by measuring serum and adi-
pose tissue levels of IL-1Ra. The serum levels of IL-1Ra 30
min after the last injection of anakinra or placebo were
735  86 after anakinra and 0.7  0.1 g/liter after pla-
cebo, P 0.001. Levels of IL-1Ra in adipose tissue lysates
were 29.2 7.5 after anakinra and 1.8 0.4 ng/liter after
placebo, corrected for protein levels,P0.05. Therewere
no carry-over effects detected.
Systemic inflammation
Inasmuch IL-1Ra has been attributed with antiinflam-
matory effects (21), we measured several markers indica-
tive of systemic inflammation. hsCRP levels (anakinra
3.57  1.40 vs. placebo 5.37  1.78 mg/liter, P  0.05)
(Fig. 3A) and leukocyte counts (anakinra 5.32 0.41 vs.
placebo 6.390.57109/liter,P0.002) (Fig. 3B)were
significantly reduced in study subjects after anakinra
treatment.
Insulin sensitivity and -cell function
Although participants were clearly insulin resistant as il-
lustrated by an insulin sensitivity index of 2.4  102 
0.3102mol/kg1 min1 pmol1 insulinafterplacebo
treatment (normal range in lean subjects 4.0–7.0  102
mol/kg1  min1  pmol1 insulin) (22), treatment with
anakinra for4wkdidnot result inan improvement in insulin
sensitivity (anakinra 2.8 102  0.5 102 vs. placebo
2.4 102  0.3 102 mol/kg1  min1  pmol1 in-
sulin,P0.15) (Fig. 2A).AverageHbA1c (anakinra 5.57
FIG. 3. Effect of anakinra on inflammation and -cell function. hsCRP
(A) and leukocyte count (B) after treatment with placebo and anakinra
are shown. C, Disposition index, calculated as the change in circulating
insulin concentration during the first 30 min of the OGTT, divided by
the change in the circulating glucose concentration during the first 30
min of the oral glucose tolerance test. D, Area under the curve for C-
peptide during the OGTT. E, Fasting proinsulin to insulin ratio. Data are
represented as mean  SEM. *, P  0.05; **, P  0.01.
TABLE 1. Baseline characteristics of the participants
Characteristic
Age 53.6  2.8
Sex (male:female) 4: 9
Body mass index (kg/m2) 33.2  1.3
Waist circumference (cm) 110.5  3.2
Blood pressure (mm Hg)
Systolic 143.8  2.8
Diastolic 83.3  2.5
Fasting glucose (mmol/liter) 5.49  0.15
HbA1c (%) 5.58  0.09
CRP (mg/liter) 5.62  0.08
Hemoglobin (mmol/liter) 8.48  0.18
Leucocytes (109/liter) 6.49  0.54
Cholesterol (mmol/liter)
Total 5.68  0.32
HDL 1.02  0.07
LDL 3.63  0.30
Triglycerides 2.85  0.50
IL-1Ra (g/liter) 0.76  0.14
HOMA-IR (mmol/pmol) 5.67  0.64
Medication with antiinflammatory
effects (number of study subjects)
Simvastatin (20 mg/d) 3
Atorvastatin (40 mg/d)
Lisinopril (20 mg/d)
Aspirin (100 mg/d) 1
CRP, C-reactive protein; HDL, high-density lipoprotein cholesterol; LDL,
low-density lipoprotein; HOMA-IR, homeostasis model assessment
insulin resistance index.
FIG. 2. Effects of anakinra on insulin sensitivity and adipose tissue. A,
Insulin sensitivity index after treatment with placebo and anakinra are
represented for each individual participant; black dashes represent mean
values. B, Injection site reaction as experienced by one of the participants
of the study. C, CD68 staining images of sc adipose tissue of an individual
participant after placebo and after anakinra treatment. D, Correlation of
the change in insulin sensitivity index after anakinra treatment compared
with placebo with the severity of macrophage infiltration into the adipose
tissue after anakinra treatment compared with placebo.
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0.11 vs. placebo 5.62 0.08%, P 0.35) and fasting glu-
cose (anakinra 5.34 0.13 vs. placebo 5.46 0.15 mmol/
liter, P 0.17) levels were unchanged after anakinra treat-
ment. Inasmuch no stable isotopes were used during the
clamp, we were unable to determine the effects of anakinra
treatment on liver insulin sensitivity levels. Alternatively,
liver insulin sensitivitywas estimated by using data obtained
during the oral glucose tolerance test (OGTT) (23). Liver
insulin sensitivity was not different between placebo vs.
anakinra treatment (P 0.66).
ThedispositionindexduringtheOGTT[change in insulin
(0–30 min)/change in glucose (0–30 min)] improved after
anakinra treatment, P  0.04 (Fig. 3C), suggestive for a
somewhat enhanced-cell function.However,otherparam-
eters indicative for -cell function including stimulated C-
peptide levels (area under the curve during the OGTT) (Fig.
3D) and fasting proinsulin to insulin ratio (Fig. 3E) did not
differ significantly betweenplaceboandanakinra treatment.
Raw OGTT data are represented in Supplemental Fig. 1,
published on The Endocrine Society’s Journals Online web
site at http://jcem.endojournals.org.
Based on OGTT criteria, five of the study participants
had impaired glucose tolerance. In this group no statisti-
cally significant differences in insulin sensitivity or -cell
function were found, perhaps based on the small sample
size.
No significant differences in triglycerides, high-density
lipoprotein cholesterol, low-density lipoprotein choles-
terol, and total cholesterol were present between placebo
and anakinra treatment.
Adipose tissue
The systemic low-grade inflammatory reaction charac-
teristic for obesity is mainly inflicted by inflammation in
the adipose tissue (3). The inhibition of IL-1 by IL-1Ra
(active substance of anakinra) is expected to reduce this
inflammatory reaction. However, the vehicle of anakinra
is known to induce an injection site reaction during the
first weeks of treatment in a majority of patients (16). We
performed fat biopsies to study the local effects of anak-
inra treatment in abdominal sc adipose tissue.
Immunohistochemical visualization of macrophages
using CD68 staining revealed an increased number of
macrophages in the adipose tissue after anakinra treat-
ment (0.28 0.05 vs. 0.11 0.01 macrophages per adi-
pocyte, P 0.005) (Fig. 2C). In addition, IL-6 concentra-
tions in adipose tissue tended to be higher after anakinra
treatment (anakinra 26.9  12.4 g/g adipose tissue vs.
placebo 5.7 1.2 g/g adipose tissue, P 0.07), sugges-
tive of an enhancement in inflammatory properties of the
adipose tissue. Moreover, expression levels of adipogenic
genes determined by quantitative PCR analysis in sc adi-
pose tissue revealed significantly decreased levels of
PPAR (P  0.03) and FABP4 (P  0.04), whereas adi-
ponectin tended to decrease (P  0.07) after anakinra
treatment.
The severity of the inflammatory reaction in the ab-
dominal sc adipose tissue, reflected by the number of in-
filtratingmacrophages after anakinra treatment, was neg-
atively correlated with the difference in individual subject
insulin sensitivity level after anakinra treatment (R2 
0.46, P  0.01) (Fig. 2D).
Subgroup analysis, using an increase in macrophage
influx of greater than 300% after anakinra treatment as a
cutoff point, unveiled that in study subjectswith low levels
of infiltrating macrophages, insulin sensitivity after anak-
inra treatment improved significantly by 39  9% [95%
confidence interval (CI) 18–61%, P  0.003] compared
with placebo, whereas in subjects with more than a 3-fold
increase in infiltratingmacrophages, insulin sensitivity de-
creased by14 12% (95%CI47 to 19%, P 0.31).
The average insulin sensitivity of subjects with low mac-
rophage influx was 53% (95% CI 20–86%, P  0.006)
better as compared with subjects with high macrophage
influx. Levels of circulating hsCRP were comparable in
both groups. Adipose tissue IL-6 appeared lower in sub-
jects with no or mild infiltration of macrophages com-
pared with the subjects with extensive infiltration, al-
though the difference did not attain statistical significance
(13.7 5.9 vs. 53.2 34.4g/g adipose tissue,P 0.14).
Discussion
The present study did not find an improvement in insulin
sensitivity after 4 wk of treatment with the IL-1Ra anak-
inra in an insulin-resistant population. The selected study
population enabled us to analyze the effects of an antiin-
flammatory intervention on insulin sensitivitywithout the
potential interference of antidiabetic medication and the
confounding effects of changing glycemic control.
In accordance with earlier findings in a population of
type 2 diabetic patients (15), we were unable to detect an
improvement in insulin sensitivity after anakinra treat-
ment our study population. However, an animal study
using XOMA 052 (anti-IL-1 antibody) has reported a
positive effect on both insulin sensitivity and -cell func-
tion (11). Another animal study using 1400.24.17 (anti-
IL-1 antibody) showed reduced HbA1c after 18 wk of
treatmentwithout consistent improvements in insulin sen-
sitivity and glucose tolerance (24). An important differ-
ence between the animal studies vs. the human trial of
Larsen et al. (15) and our trial is the use of specific anti-
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IL-1 antibodies in the animal trials. The human trials do
use IL-1Ra, which has effects on both IL-1 and IL-1.
There are a number of explanations for the lack of im-
provement in insulin sensitivity in our study.
First, circulating levels of IL-1Ra in study participants
may vary considerably. It has been suggested that IL-1Ra
levels at baseline determine the effects of anakinra treat-
ment, with thosewith the lowest level showing the highest
response (25). Nevertheless, in our study we were unable
to find any association between IL-1Ra levels at baseline
and changes in insulin sensitivity after anakinra treatment,
which largely excludes the possibility that insufficient pro-
duction of IL-1Ra contributes to the development of in-
sulin resistance in our study subjects. Noticeably, also in
our population, the baseline IL-1Ra levels were quite
variable.
Second, the dose of IL-1Ra used in our study or infil-
tration into target tissues may have been insufficient.
However, the dosage used in our study was 1.5 times
higher than normally used and concentrations of IL-1Ra
in the circulation were 1000-fold higher compared with
placebo treatment, accompanied by a 16-fold increase in
IL-1Ra levels in adipose tissue after anakinra treatment.
Moreover, the reduction in inflammatorymarkers includ-
ing hsCRP and leukocytes suggest that treatment with
anakinra did provoke a systemic antiinflammatory effect.
Third, because adipose tissue is a causative factor for
systemic low-grade inflammation during the development
of obesity (3) and is partly responsible for determining
systemic insulin sensitivity, we evaluated local effects of
anakinra inadipose tissuebiopsies.Basedonearlier results
of in vitro studies that demonstrated lower insulin sensi-
tivity and reduced levels of theadipogenicmarkersPPAR
and FABP4 after IL-1 treatment of adipocytes, we hy-
pothesized that inhibiting IL-1 signaling by anakinra
treatment would enhance adipogenic gene expression lev-
els (8, 26). In contrast, anakinra treatment led to reduced
gene expression levels of PPAR and FABP4 and in-
creased levels of macrophage infiltration. This finding is
surprising because treatment with anakinra reduced sys-
temic levels of inflammation. The influx of macrophages,
probably accompanied by other immune cells, is most
likely not the direct effect of IL-1Ra butmight be the effect
of one of the additives present in the commercial prepa-
rations of anakinra. Injection site reaction is awell-known
side effect of anakinra during the first weeks of treatment
and is known to result in the infiltration of macrophages
(27). Earlier studies have demonstrated the importance of
infiltrating macrophages in the sc adipose tissue in pro-
voking systemic insulin resistance (28). The lack of posi-
tive findings of our study on insulin sensitivity may thus
(partly) be explained by negative effects of local adipose
tissue inflammatory injection site reactions on insulin sen-
sitivity. In line with this explanation, the severity of the
inflammatory reactioncausedby the injection site reaction
in sc adipose tissue turned out to be inversely correlated
with the improvement in systemic insulin sensitivity after
anakinra treatment.
The relation between IL-1, inflammation in adipose
tissue, and its effect on systemic insulin sensitivity by af-
fecting systemic inflammation iswell known.However, in
this study local inflammation in the abdominal sc adipose
tissue is correlated with systemic insulin sensitivity, with-
out influencing systemic inflammation. This can partly be
explained by a direct negative effect of local inflammation
on the local adipose tissue. Alternatively, the inflamed ad-
ipose tissue might have led to an altered adipokine secre-
tion profile that negatively interfered with insulin sensi-
tivity in peripheral organs including liver and muscle.
It should be stressed that the adipose tissue biopsy was
not taken out of an area with macroscopic inflammation.
However, because injection sites were varied over time (as
advised) over different abdominal areas, the diffuse in-
flammation observed may reflect tissue responses from
earlier injections.
In respect to -cell function, we found a hint toward
improved insulin secretion capacity as reflected by the dis-
position index, although the other evaluated parameters
for -cell function did not improve significantly. How-
ever, the disposition index is known to be an independent
predictor for the development of type 2 diabetes mellitus
(29). It should also be stressed that the participants in this
study were selected for insulin resistance (obesity/meta-
bolic syndrome) but not insulin secretion deficits. All sub-
jects had glucose levels in the nondiabetic range.
This is the first study that has specifically studied the
effects of IL-1 blockade on insulin sensitivity in human
nondiabetic subjects. A similar study has been performed
in subjects with type 2 diabetes (15). This latter study
measured both insulin sensitivity and insulin secretion be-
fore and after 13 wk of treatment. Glycemic control im-
proved after 4 and 13 wk of treatment, and this was at-
tributed to an improvement in -cell function, whereas
insulin sensitivity appeared to be unchanged. As such, our
findings are in line with the results of the study performed
by Larsen et al. (15). The fact that we did not find a clear
improvement in insulin secretion may be explained by the
differences in study population. The subjects included in
our study were nondiabetic and had normal levels of
HbA1c and fasting glucose at baseline and had no indi-
cation of defective -cell function, whereas Larsen et al.
included patients with type 2 diabetes mellitus.
The dose and duration of treatment were different in
our study comparedwithLarsen et al. (15) (100mgsconce
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daily for 13 wk by Larsen et al. vs. 150 mg sc once daily
for 4 wk in our study). The larger dose and shorter treat-
ment period used in our study may have aggravated the
injection site reaction because adverse effects are dose de-
pendent and vanish after prolonged treatment (16). The-
oretically a prolonged treatment of subjects in our study
could have resulted in waning of side effects because in-
jection site reactions of anakinra do disappear after 4–6
wk of treatment and may have revealed an improvement
in insulin sensitivity. However, a prolonged treatment pe-
riodwould substantially extend the duration of the (cross-
over) trial, increasing the risk for carry-over effects,
whereas biological effects of IL-1 blockade were expected
to be present within weeks.
In summary, the results of this study do not support the
concept that blockade of IL-1 by anakinra treatment im-
proves insulin sensitivity. It cannot be fully excluded,
though, that potentially positive effects on insulin sensi-
tivity are (partly) offset by local inflammatory reactions at
the injection site of anakinra. Whether treatment with
other modalities that block IL-1 but do not produce local
injection site effects potentially has a beneficial effect on
insulin sensitivity remains to be determined. The present
study results support a beneficial effect of blocking IL-1on
-cell function.
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